Clinical Trial according to §23b MPG on Performance, safety and clinical benefit of hysan Nasensalbe (HYNASA-2018)

Clinical Trial according to §23b MPG on Performance, safety and clinical benefit of hysan Nasensalbe (HYNASA-2018) - HYNASA-2018

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00015670

Enrollment

100

Registered

2018-10-01

Start date

2018-10-31

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J31.0 J01

Interventions

Group 1: hysan nasal ointment, vitamin-A-containing nasal ointment, Treatment over a period of appr. 10 days Group 2: Control Group, no specific treatment of anterior part of the nose

Eligibility

Sex/Gender

All

Age

12 Years to No maximum

Inclusion criteria

Inclusion criteria: - Adults and children above 12 years - Sore nose - At least two symptoms must be at least assessed as "mild" or one symptom as "strong" or "very strong" - Informed consent

Exclusion criteria

Exclusion criteria: Current Treatment of sore nose Expected non-compliance, no cooperation participation in another trial within the last 4 weeks and/or contemporaneously to this Trial

Design outcomes

Primary

Measure	Time frame
Daily average values of four main clinical symptoms for each patient	—

Secondary

Measure	Time frame
Single items of clincal main symptoms Assessment of hysan Nasensalbe Assessment by physicians Global assessment by patients Global assessemnt by physicians	—

Countries

Germany

Contacts

Public ContactPeter Meiser

URSAPHARM Arzneimittel GmbH

info@ursapharm.de06805-9292-0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026